Different effects of oxycodone and remifentanil in patients undergoing ultrasound-guided percutaneous radiofrequency ablation of hepatic cancer: a randomized trial
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 13, 365-372
- https://doi.org/10.2147/dddt.s188728
Abstract
Background: Percutaneous radiofrequency ablation (RFA) is a recently introduced alternative technique for the treatment of hepatic cancer. Anesthesia is required for RFA of hepatic cancer to achieve patient comfort and immobilization during this painful procedure. The purpose of this study was to investigate the analgesic efficacy and evaluate the safety of a single intravenous injection of oxycodone hydrochloride for this procedure. Patients and methods: A total of 120 American Society of Anesthesiologists class I–II grade patients for elective ultrasound-guided percutaneous RFA were enrolled in this randomized controlled trial. Patients were randomized (1:1) to receive either a single intravenous injection of oxycodone (group O) or continuous infusion of remifentanil (group R). Both groups received the continuous infusion of dexmedetomidine for sedation. Visual analog scale (VAS), rescue analgesic, and side effects were checked during the periprocedural period. In addition, patient and oncologist satisfaction on a scale of 1–5 were determined. Results: VAS score in group O was significantly lower than in group R at 1, 2, and 3 hours after RFA, and patients in group O required analgesics significantly later and less doses in the first 24 hours after RFA. The occurrence of unwanted body movements was significantly lower in group O. We found no complications including allergic reaction, excessive sedation, and chest wall rigidity in all patients. The patient satisfaction score was significantly higher in group O than that in group R. Conclusion: Ultrasound-guided percutaneous RFA for hepatic cancer can be completed both with continuous infusion of remifentanil or a single intravenous injection of oxycodone. However, oxycodone hydrochloride provides better patient experience with higher satisfactory score and less unwanted body movements, relieves post-procedural pain better, and is not associated with an increase in adverse effects.Keywords
This publication has 31 references indexed in Scilit:
- Procedural sedation: A review of sedative agents, monitoring, and management of complicationsSaudi Journal of Anaesthesia, 2011
- A comparison of the respiratory effects of oxycodone versus morphine: a randomised, double-blind, placebo-controlled investigation*Anaesthesia, 2010
- Radiofrequency Ablation of Inoperable Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- RFA for Liver Tumors: Does It Really Work?The Oncologist, 2006
- A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain modelPain, 2006
- Opioids and the gut: pharmacology and current clinical experienceNeurogastroenterology & Motility, 2004
- Short-term infusion of the μ-opioid agonist remifentanil in humans causes hyperalgesia during withdrawalPain, 2003
- Practice Guidelines for Sedation and Analgesia by Non-AnesthesiologistsAnesthesiology, 2002
- An Operating Room Scheduling Strategy to Maximize the Use of Operating Room Block TimeAnesthesia & Analgesia, 1999
- The intrinsic antinociceptive effects of oxycodone appear to be κ -opioid receptor mediatedPain, 1997